COMMUNIQUÉS West-GlobeNewswire

Natus Medical Board of Directors Mails Letter to Shareholders
04/06/2018
Recommends Voting on the WHITE Proxy Card FOR the Election of Doris Engibous and Robert Weiss Shareholders Should Not Vote for Removal of Chairman Robert Gunst Illustrates Highly-Qualified and Committed Directors with [...]
Interpace Diagnostics to Attend and Present at the 8th Annual LD Micro Invitational Conference
04/06/2018
PARSIPPANY, N.J., June 04, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically [...]
Oxford Immunotec Announces Data Presentations for T-SPOT®.CMV Test at the 2018 American Transplant Congress
04/06/2018
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 04, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that data from studies utilizing the [...]
Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment
04/06/2018
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) , an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the initiation of an [...]
Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
04/06/2018
-- Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from bench to human [...]
Cesca Therapeutics Announces Reduction in Operating Expenses
04/06/2018
RANCHO CORDOVA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies [...]
Viveve Announces Settlement of Patent Infringement Litigation with Thermi
04/06/2018
ENGLEWOOD, Colo., June 04, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the [...]
Evolus to Present at the Jefferies 2018 Global Healthcare Conference
04/06/2018
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (“Evolus”) (NASDAQ:EOLS), a premiere aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, [...]
Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)
04/06/2018
Phase 2 to Continue Enrolling Colorectal Cancer Patients with PIK3CA Mutation SOUTH SAN FRANCISCO, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology [...]
DBV Technologies : Correctif - Assemblée Générale Mixte du 22 juin 2018 - Modalités de mise à disposition des documents préparatoires à l'Assemblée
04/06/2018
Montrouge, France, le 1 juin (07h30 CEST) 2018 Assemblée Générale Mixte du 22 juin 2018 Modalités de mise à disposition des documents préparatoires à l'Assemblée DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - [...]
Athenex Names Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific
04/06/2018
BUFFALO, N.Y., June 04, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing Innovative Oncology Therapeutics
04/06/2018
- Tolerability and proof-of-mechanism for lead candidate AVB-S6-500, a novel GAS6-AXL pathway inhibitor, established in ongoing Phase 1 clinical study - Multi-study clinical development program in combination with [...]
Checkpoint Therapeutics to Participate in June Investor Conferences
04/06/2018
NEW YORK, June 04, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]
Soleno Therapeutics To Present Corporate Update at the BIO International Convention
04/06/2018
REDWOOD CITY, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
04/06/2018
Independent Data Monitoring Committee’s (DMC) review of available safety data supports continuing with study as planned; FORT Study now open to pediatric patients aged 6 to 17 Top-line data anticipated in the second [...]
Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
04/06/2018
SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz, RPh, to the newly created role of [...]
Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony
04/06/2018
ATLANTA, GA and BOTHELL, WA, June 04, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral [...]
Novo Nordisk A/S - Share repurchase programme
04/06/2018
Bagsværd, Denmark, 4 June 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), [...]
Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253
04/06/2018
Identification of APTO-253 target leading to inhibition of MYC expression in AML and hypersensitivity of cancer cells with BRCA1/2 deficiencies SAN DIEGO and TORONTO, June 04, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences [...]

Pages